ILAP: Improving access to innovative oncology treatments
With no new first-line treatment for de-differentiated liposarcoma in over…
With no new first-line treatment for de-differentiated liposarcoma in over forty years, Dr Christoph Zehendner, Medical Director of Boehringer Ingelheim UK and Ireland discusses the company’s ILAP designation of its investigational, innovative treatment.